Hospital Universitario da A Coruna
- Address
- Lugar Jubias De Arriba 84, 15006 A Coruna Galicia, Spain
Oncology and Neoplasm Research
At Hospital Universitario da A Coruna, the Oncology department is running clinical trials focused on cancer care, with studies aimed at improving treatment options for advanced and metastatic malignancies. The research includes testing new therapies, assessing how well they work, and exploring better ways to manage difficult-to-treat tumors.
- Advanced RET-altered malignancies and RET fusion-positive non-small cell lung cancer
- Advanced/metastatic breast cancer with a focus on hormone receptor-positive disease
- Low-grade upper tract urothelial cancer and treatment effectiveness in urinary tract tumors
- Non-small cell lung cancer studies evaluating new approaches for advanced disease
These trials are primarily designed to test innovative cancer therapies, measure disease control, and support better outcomes for patients with hard-to-treat solid tumors.
Virus Diseases and COVID-19 Studies
The site is also involved in research on virus diseases, especially Coronavirus Disease 2019 (COVID-19). These studies are examining new treatment strategies for people with weakened immune systems, with the goal of improving symptom control and viral response.
- COVID-19 in severely immunocompromised adults
- Evaluations of antiviral treatment approaches for better clinical and virological outcomes
- Research aimed at improving care for vulnerable patients with limited immune defenses
This work reflects a broader effort to refine treatment options for infectious disease patients, especially those at higher risk of complications.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 28 therapeutic areas and 15 of 574 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 561 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 122 by active trials.
- 1AstraZeneca AB15active
lock +121 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB37trials
lock +74 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Universitario da A Coruna
lock Showing 1 of 515 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 2022-501606-35-00 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). | AbbVie Deutschland GmbH & Co. KG | Phase I | Not Yet Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 574 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 53 | Unknown | 2017-05-26 | 2026-06-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.